Fig. S4.

Effect of over-expression or silencing TLR2 or TLR4 on bulk cancer cell stemness and radiotherapy resistance. (a) FACS analysis of the percentage of CD133⁺ cancer cells in TLR2-overexpressing or TLR2 siRNA-transfected bulk cells. (b) CCK8 testing was performed to assess the viability of CD133⁺ SW1990 cancer cells overexpressing TLR2 or transfected with TLR2 siRNA, followed by treatment with 150 ng/mL rhHMGB1. (c) CCK8 testing was performed to assess the viability of CD133⁺ SW1990 cancer cells overexpressing TLR4 or transfected with TLR4 siRNA, followed by treatment with 150 ng/mL rhHMGB1. Experiments were repeated three times, and the data are expressed as the mean ± SEM. Statistical analysis was performed using Student's t-test (b, c).